Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The initial dose of this medicine should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom sitagliptin monotherapy does not provide adequate blood glucose control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
2. Patients receiving metformin:
- For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients with inadequate blood glucose control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment must not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately.
Improvement of glycemic control in patients with type 2 diabetes
View approved original textHide original text
This medication helps patients with type 2 diabetes to achieve better blood sugar control. Sitagliptin and metformin work together to complement the effects of diet and exercise, improving blood sugar levels. This aids in diabetes management.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The initial dose of this medicine should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom sitagliptin monotherapy does not provide adequate blood glucose control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily.
2. Patients receiving metformin:
- For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin.
3. Patients with inadequate blood glucose control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment must not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately.
Precautions
This medication consists of two components, each with specific precautions.
Firstly, one of the components may cause hypersensitivity reactions. Such reactions can range from severe allergic responses to severe skin rashes or inflammation, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking the medication, discontinue use immediately and consult a doctor.
Secondly, this medication may cause pancreatitis, which is an inflammation of the pancreas. Symptoms such as abdominal pain, nausea, or vomiting should prompt immediate medical attention.
Thirdly, the other component may cause severe lactic acidosis, a rare but life-threatening metabolic complication. Lactic acidosis occurs when lactate accumulates excessively in the body, presenting symptoms like muscle pain, weakness, difficulty breathing, and abdominal pain. If these symptoms arise, discontinue the medication and inform healthcare professionals immediately.
Additionally, this medication should not be administered to patients with impaired kidney function, severe heart or liver issues, pregnant or breastfeeding women, and those with certain acute conditions.
While taking this medication, be cautious of irregular or insufficient food intake, intense exercise, or concurrent use of other medications, as this may increase the risk of hypoglycemia or lactic acidosis.
Regular checks of blood sugar, kidney function, liver function, and vitamin B12 levels should be conducted to ensure no abnormalities arise during treatment.
Symptoms of hypoglycemia include dizziness, sweating, and severe hunger, and the risk of low blood sugar may increase when this medication is taken with other hypoglycemic agents, requiring possible dosage adjustments depending on the medications being used.
Furthermore, this medication should be temporarily stopped before surgeries, and it should also be interrupted for a period before and after tests using iodinated contrast agents.
Excessive alcohol consumption should be avoided during treatment as alcohol may increase the risk of side effects from this medication.
Lastly, in case of an overdose, seek immediate medical assistance, as some components can be removed through dialysis.
This medication should not be administered to children, particularly those under 18 years of age, as its safety and efficacy have not been established in this age group.
In elderly patients, reduced kidney function may occur, necessitating more cautious management and regular monitoring during treatment.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 23 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
dermatitis
anorexia
weight loss
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
gastrointestinal disturbance
itching
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. The optimal storage temperature is between 1 degree and 30 degrees Celsius at room temperature.
Appearance and packaging
Appearance
Light pink oval film-coated tablets
Package unit
30 tablets/bottle, 120 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.